As we reach the middle of June, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI. We're currently running a 40% OFF ASCO sale, learn more here.
Table 1. BPIQ company weekly/monthly moves and YTD moves
Category | Weekly Move 6/20-6/24 | YTD Move |
|---|---|---|
All BPIQ Companies | +9.00% | -44.44% |
CAR-T Companies | +15.42% | -53.22% |
Gene Editing Companies | +19.31% | -49.27% |
XBI | +13.98% | -31.17% |
See the biggest moves from last week below:
Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!
*We never send you spam - unsubscribe anytime
Highlights for the week
Biggest positive move
#VALN +98.9% Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
Biggest negative move
#ATHA -68.1% Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Additional weekly big moves
#ANEB +84.1% Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
#RAIN +61.2%
#OMGA +59.6% Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer
#MDNA +53.2% Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron
#RMTI +51.9% Rockwell Medical Provides Corporate and Clinical Update
#IKNA +48.8% Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma
#GLUE +48.6%
#IPHA +44.5% Innate Pharma to participate in upcoming investor conference
#CLVS +44.1%
#CBAY +43.2% CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022
#ANGN +42.0%
#PTCT +41.6% PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy.
#KTRA +40% Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference
#VBIV +37.3% VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
#BMEA +36.6% Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial
#QURE +35.4% uniQure N.V. - uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
#ORMP +31.7%
#OMER +30.5%
#NVAX +28.4% Novavax Files Supplement to a New Drug Submission in Canada for Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17
#VACC +23.1% Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1
#RDUS +19.9% Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital
#PRTK +17.8% Paratek Pharmaceuticals' NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)
#FUSN -15.4% Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1
#APLT -19.1% Applied Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants
#ACAD -23.2% Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis.
#NMTR -25.5% 9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
#ADXN -26.7% Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate
#LBPH -27.5%
#IDRA -29.8%
#LBPS -31.8%
#IFRX -35.5%
Highlights for next week
To see next week's Big Movers HERE, subscribe. Learn more here.
$SPRO Tebipenem PDUFA
See our June PDUFA list for remaining target action date for the month and our new July PDUFA list
See our Big Movers post to learn about upcoming Movers throughout June and PDUFAs, after subscribing. Learn more here.
Comments